Effects of pioglitazone and vildagliptin on coagulation cascade in diabetes mellitus-targeting thrombogenesis

Expert Opinion on Therapeutic Targets

Volumn 17, Issue 6, 2013, Pages 627-639

  Khan, Sana ^a   Khan, Saba ^a   Imran, Mohammed ^b   Pillai, Krishna Kolappa ^a   Akhtar, Mohd ^a   Najmi, Abul Kalam ^a  

^a HAMDARD UNIVERSITY   (India)

^b HAMDARD UNIVERSITY   (India)

Author keywords

Atherothrombotic disease; Cardiovascular disease; Coagulation factors; Inflammatory biomarkers; Pioglitazone; Thrombosis; Type 2 diabetes mellitus; Vildagliptin

Indexed keywords

FIBRINOGEN; GLITAZONE DERIVATIVE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PIOGLITAZONE; VILDAGLIPTIN;

ANTICOAGULATION; ANTIINFLAMMATORY ACTIVITY; BLOOD CLOTTING; CARDIOVASCULAR RISK; DRUG EFFECT; DRUG MECHANISM; HUMAN; HYPERGLYCEMIA; INSULIN RESISTANCE; NON INSULIN DEPENDENT DIABETES MELLITUS; REVIEW; THROMBOSIS;

ADAMANTANE; ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTICOAGULANTS; BLOOD COAGULATION; BLOOD COAGULATION FACTORS; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DISEASE PROGRESSION; FIBRINOLYTIC AGENTS; HUMANS; HYPOGLYCEMIC AGENTS; NITRILES; PYRROLIDINES; THIAZOLIDINEDIONES; THROMBOSIS;

EID: 84877850505     PISSN: 14728222     EISSN: 17447631     Source Type: Journal    
DOI: 10.1517/14728222.2013.764991     Document Type: Review

References (99)

1. Stunvoll M, Goldstein BJ, van Haeften TW. Type 2 diabetes: principles of pathogenesis and therapy. Lancet 2005;365:333-46
2. The World health statistics 2012 reports. Geneva: world Health Organization. 2012. Available from: http://www.who. int/mediacentre/news/ releases/2012/ world-health-statistics-20120516/en/ [Last accessed 10 October 2012]
3. Bakker W, Eringa EC, Sipkema P, van Hinsbergh VWM. Endothelial dysfunction and diabetes: roles of hyperglycaemia, impaired insulin signalling and obesity. Cell Tissue Res 2009;335:165-89
4. Pandolfi A, De Filips EA. Chronic hyperglycemia and nitric oxide bioavailability play a pivotal role in pro-atherogenic vascular modifications. Genes Nutr 2007;2:195-208
5. McGill HD, McMahan CA. Determinants of atherosclerosis in the young: pathobiological Determinants of Atherosclerosis in Youth (PDAY) Research Group. Am J Cardiol 1998;82:30-6
6. American Diabetes Association. Consensus statement role of cardiovascular risk factors in prevention and treatment of macrovascular disease in diabetes. Diabetes Care 1989;12:573-9
7. Gough SCL, Grant PJ. The fibrinolytic system in diabetes mellitus. Diabetic Med 1991;8:898-905
8. Staels B. PPARgamma and atherosclerosis. Curr Med Res Opin 2005;21(Suppl 1):13-20
9. Rizos CV, Liberopoulos EN, Mikhailidis DP, Elisaf MS. Pleiotropic effects of thiazolidinediones. Expert Opin Pharmacother 2008;9:1087-108
10. Shah Z, Kampfrath T, Deiuliis JA, et al. Long-Term Dipeptidyl-Peptidase 4 Inhibition Reduces Atherosclerosis and Inflammation via Effects on Monocyte Recruitment and Chemotaxis. Circulation 2011;124(21):2338-49
11. Anagnostis P, Athyros VG, Adamidou F, et al. Glucagon-like peptide-1-based therapies and cardiovascular disease: looking beyond glycaemic control. Diabetes Obes Metab 2011;13:302-12 .
12. Keating GM. Vildagliptin: a review of its use in type 2 diabetes mellitus. Drugs 2010;70:2089-112
13. Guerci B, Bohme P, Kearney-Schwartz A, et al. Endothelial dysfunction and type 2 diabetes. Diabetes Metab 2001;27:436-47
14. Ferroni P, Basil S, Falco A, Davi G. Platelet activation in type 2 diabetes mellitus. J Thromb Haemost 2004;2:1282-91
15. Ajjan R, Grant PJ. Coagulation and atherothrombotic disease. Atherosclerosis 2006;186:240-59
16. Ajjan RA, Ariens RA. Cardiovascular disease and heritability of the prothrombotic state. Blood Rev 2009;23:67-78
17. Dionyssiou-Asteriou A, Papastamatiou M, Vatalas IA, et al. Serum apolipoprotein AI levels in atherosclerotic and diabetic patients. Eur J Vasc Endovasc Surg 2002;24:161-5
18. Dandona P, Aljada A, Mohanty P, et al. Insulin inhibits intranuclear nuclear factor kappaB and stimulates IkappaB in mononuclear cells in obese subjects: evidence for an anti-inflammatory effect? J Clin Endocinol Metab 2001;86:3257-65
19. Cusi K, Maezono K, Osman A, et al. Insulin resistance differentially affects the PI 3-kinase- and MAP kinase-mediated signaling in human muscle. J Clin Invest 2000;105:311-20
20. Meigs JB, Mittleman MA, Nathan DM, et al. Hyperinsulinemia, hyperglycemia, and impaired hemostasis: the Framingham Offspring Study. JAMA 2000;283:221-8
21. Willerson JT, Ridker PM. Inflammation as a cardiovascular risk factor. Circulation 2004;109(Suppl 2):2-10
22. Vlassara H, Brownlee M, Manogue KR, et al. Cachectin/TNF and IL-1 induced by glucose-modified proteins; role in normal tissue remodeling. Science 1988;240:1546-8
23. Ford ES. Body mass index, diabetes, and C-reactive protein among U.S. adults. Diabetes Care 1999;22:1971-7
24. Salmi M, Stolen C, Jousilahti P, et al. Insulin-regulated increase of soluble vascular adhesion protein-1 in diabetes. Am J Pathol 2002;161:2255-62
25. Corti R, Hutter R, Badimon JJ, Fuster V. Evolving concepts in the triad of atherosclerosis, inflammation and thrombosis. J Thromb Thrombolysis 2004;17:35-44
26. Nathanson D, Nystrom T. Hypoglycaemic treatment of type 2 diabetes: targeting the endothelium. Mol Cell Endocrinol 2009;297:112-26
27. Kazama Y, Hamamoto T, Foster DC, Kisiel W. Hepsin a putative membrane-associated serine protease, activates human factor VII and initiates a pathway of blood coagulation on the cell surface leading to thrombin formation. J Biol Chem 1995;270:66-72
28. Alberio L, Safa O, Clemetson KJ, et al. Surface expression and functional characterization of alpha-granule factor V in human platelets: effects of ionophore A23187, thrombin, collagen, and convulxin. Blood 2000;95:1694-702
29. Ceriello A. Fibrinogen and diabetes mellitus: is it time for intervention trials? Diabetologia 1997;40:731-4
30. Carr ME. Diabetes mellitus: a hypercoagulable state. J Diabetes Complications 2001;15:44-54 .
31. Madan R, Gupta B, Saluja S, et al. Coagulation profile in diabetes and its association with diabetic microvascular complications. JAPI 2010;58:481-4
32. Dunn EJ, Grant PJ. Type 2 diabetes: an atherothrombotic syndrome. Curr Mol Med 2005;5:323-32
33. Kwaan HC, Colwell JA, Cruz S, et al. Increased platelet aggregation in diabetes mellitus. J Lab Clin Med 1972;80:236-46
34. Konieczkowski M, Skrinska VA. Increased synthesis of thromboxane A (2) and expression of procoagulant activity by monocytes in response to arachidonic acid in diabetes mellitus. Prostaglandins Leukot Essent Fatty Acids 2001;65:133-8
35. Folsom AR, Conlan MG, Davis CE, et al. Atherosclerosis Risk in Communities (ARIC) Study Investigators. Relations between hemostasis variables and cardiovascular risk factors in middle-aged adults. Ann Epidemiol 1992;2:481-94
36. Duncan BB, Schmidt MI, Offenbacher S, et al. The Atherosclerosis Risk in Communities (ARIC) Study, Factor VIII and other hemostasis variables are related to incident diabetes in adults. Diabetes Care 1999;22:767-72
37. Asakawa H, Tokunaga K, Kawakami F. Elevation of fibrinogen and thrombin-antithrombin III complex levels of type 2 diabetes mellitus patients with retinopathy and nephropathy. J Diabetes Complications 2000;14:121-6
38. Rao AK, Chouhan V, Chen X, et al. Activation of the tissue factor pathway of blood coagulation during prolonged hyperglycemia in young healthy men. Diabetes 1999;48:1156-61
39. Conway DS, Pearce LA, Chin BS, et al. Plasma von Willebrand factor and soluble p-selectin as indices of endothelial damage and platelet activation in 1321 patients with nonvalvular atrial fibrillation: relationship to stroke risk factors. Circulation 2002;106:1962-7
40. Colwell JA, Lyon TJ, Klein RL, et al. Atherosclerosis and thrombosis in diabetes mellitus: new aspects of pathogenesis. Levin and O'Neal's The diabetic foot 2001
41. Salomaa V, Matei C, Aleksic N, et al. Atherosclerosis Risk in Communities. Cross-sectional association of soluble thrombomodulin with mild peripheral artery disease; the ARIC study. Atherosclerosis 2001;157:309-14
42. Festa A, Agostino R, Mykkanen L, et al. The Insulin Resistance Atherosclerosis Study (IRAS). Relative contribution of insulin and its precursors to fibrinogen and PAI-1 in a large population with different states of glucose tolerance. Arterioscler Thromb Vasc Biol 1999;19:562-8
43. Pandolfi A, Cetrullo D, Polishuck R, et al. Plasminogen activator inhibitor type 1 is increased in the arterial wall of type II diabetic subjects. Arterioscler Thromb Vasc Biol 2001;21:1378-82
44. Reverter JL, Reverter JC, Tassies D, et al. Thrombomodulin and induced tissue factor expression on monocytes as markers of diabetic microangiopathy: a prospective study on hemostasis and lipoproteins in insulin-dependent diabetes mellitus. Am J Hematol 1997;56:93-9
45. Acang N, Jalil FD. Hypercoagulation in diabetes mellitus. Southeast Asian J Trop Med Public Health 1993;24(Suppl 1):263-6
46. Verges B. Clinical interest of PPARs ligands. Particular benefit in type 2 diabetes and metabolic syndrome. Diabetes Metab 2004;30:7-12
47. Chu JW, Abbasi F, Lamendola C, et al. Effect of rosiglitazone on circulating vascular and inflammatory markers in insulin-resistant subjects. Diabetes Vasc Dis Res 2005;2:37-41
48. Kruszynska YT, Yu JG, Olefsky JM, et al. Effects of troglitazone on blood concentrations of plasminogen activator inhibitor 1 in patients with type 2 diabetes and in lean and obese normal subjects. Diabetes 2000;49:633-9
49. Derosa G, Cicero AF, Gaddi A, et al. A comparison of the effects of pioglitazone and rosiglitazone combined with glimepiride on prothrombotic state in type 2 diabetic patients with the metabolic syndrome. Diabetes Res Clin Pract 2005;69:5-13
50. De Jager J, Kooy A, Lehert P, et al. Effects of short-term treatment with metformin on markers of endothelial function and inflammatory activity in type 2 diabetes mellitus: a randomized, placebo-controlled trial. J Intern Med 2005;257:100-9
51. Fonseca V, Theuma P, Mudaliar S, et al. Diabetes treatments have differential effects on non-traditional cardiovascular risk factors. J Diabetes Complications 2006;20:14-20
52. Stumvoll M, Haring HU. Glitazones: clinical effects and molecular mechanisms. Ann Med 2002;34(3):217-24
53. Gizard F, Bruemmer D. Transcriptional control of vascular smooth muscle cell proliferation by peroxisome proliferator-activated receptor-gamma: therapeutic implications for cardiovascular diseases. PPAR Res 2008;2008:429123
54. Elte JWF, Blickle JF. Reprint of: thiazolidinediones for the treatment of type 2 diabetes. Eur J Intern Med 2011;18(1):18-25
55. Pfutzner A, Marx N, Lubben G, et al. Improvement of cardiovascular risk markers by pioglitazone is independent from glycemic control: results from the pioneer study. J Am Coll Cardiol 2005;45:1925-31 .
56. Hetzel J, Balletshofer B, Rittig K, et al. Rapid effects of rosiglitazone treatment on endothelial function and inflammatory biomarkers. Arterioscler Thromb Vasc Biol 2005;25:1804-9
57. Liu HB, Hu YS, Medcalf RL, et al. Thiazolidinediones inhibit TNFalpha induction of PAI-1 independent of PPARgamma activation. Biochem Biophys Res Commun 2005;334:30-7
58. Akbiyik F, Ray DM, Gettings KF, et al. Human bone marrow megakaryocytes and platelets express PPARgamma, and PPARgamma agonists blunt platelet release of CD40 ligand and thromboxanes. Blood 2004;104(5):1361-8
59. Bodary PF, Vargas FB, King SA, et al. Pioglitazone protects against thrombosis in a mouse model of obesity and insulin resistance. J Thromb Haemost 2005;3(10):2149-53
60. Li D, Chen K, Sinha N, et al. The effects of PPAR-gamma ligand pioglitazone on platelet aggregation and arterial thrombus formation. Cardiovasc Res 2005;65(4):907-12
61. Dormandy JA, Charbonnel B, Eckland DJ, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomized controlled trial. Lancet 2005;366:1279-89 .
62. Imamoto E, Yoshida N, Uchiyama K, et al. Inhibitory effect of pioglitazone on expression of adhesion molecules on neutrophils and endothelial cells. Biofactors 1920;1:37-47
63. Polikandriotis JA, Mazzella LJ, Rupnow HL, Hart CM. Peroxisome proliferator-activated receptor gamma ligands stimulate endothelial nitric oxide production through distinct peroxisome proliferator-activated receptor gamma-dependent mechanisms. Arterioscler Thromb Vasc Biol 2005;25:1810-16
64. Berhanu P, Kipnes MS, Khan MA, et al. Effects of pioglitazone on lipid and lipoprotein profiles in patients with type 2 diabetes and dyslipidaemia after treatment conversion from rosiglitazone while continuing stable statin therapy. Diab Vasc Dis Res 2006;3:39-44
65. Szapary PO, Bloedon LT, Samaha FF, et al. Effects of pioglitazone on lipoproteins, inflammatory markers and adipokines in nondiabetic patients with metabolic syndrome. Arterioscler Thromb Vasc Biol 2006;26:182-8
66. Blann AD, Lip GY. Effects of C-reactive protein on the release of von Willebrand factor, E-selectin, thrombomodulin and intercellular adhesion molecule-1 from human umbilical vein endothelial cells. Blood Coagul Fibrinolysis 2003;14:335-40
67. Baalbaki HA, Bell DS. Insulin resistance and thrombogenesis: recent insights and therapeutic implications. Endocr Pract 2007;13:679-86
68. Zhang B, Szalkowski D, Diaz E, et al. Potentiation of insulin stimulation of phosphatidylinositol 3-kinase by thiazolidinedione-derived antidiabetic agents in Chinese hamster ovary cells expressing human insulin receptors and L6 myotubes. J Biol Chem 1994;269:25735-41
69. Kappert K, Meyborg H, Clemenz M, et al. Insulin facilitates monocyte migration: a possible link to tissue inflammation in insulin-resistance. Biochem Biophys Res Commun 2008;365:503-8
70. Campbell IW. Long-term glycaemic control with pioglitazone in patients with type 2 diabetes. Int J Clin Pract 2004;58:192-200
71. Seufert J, Urquhart R. 2-year effects of pioglitazone add-on to sulfonylurea or metformin on oral glucose tolerance in patients with type 2 diabetes. Diabetes Res Clin Pract 2008;79:453-60
72. Doran AC, Meller N, McNamara CA. Role of smooth muscle cells in the initiation and early progression of atherosclerosis. Arterioscler Thromb Vasc Biol 2008;28:812-19
73. Aizawa Y, Kawabe J, Hasebe N, et al. Pioglitazone enhances cytokine-induced apoptosis in vascular smooth muscle cells and reduces intimal hyperplasia. Circulation 2001;104:455-60
74. Mieszczanska H, Kaba NK, Francis CW, et al. Effects of pioglitazone on fasting and postprandial levels of lipid and hemostatic variables in overweight non-diabetic patients with coronary artery disease. J Thromb Haemost 2007;5:942-9
75. Borchert M, Schondorf T, Lubben G, et al. Review of the pleiotropic effects of peroxisome proliferatoractivated receptor gamma agonists on platelet function. Diabetes Technol Ther 2007;9:410-20
76. Berneis K, Rizzo M, Stettler C, et al. Comparative effects of rosiglitazone and pioglitazone on fasting and postprandial low-density lipoprotein size and subclasses in patients with type-2 diabetes. Expert Opin Pharmacother 2008;9:343-9
77. Rizzo M, Christ ER, Rini GB, et al. The differential effects of thiazolidindiones on atherogenic dyslipidemia in type-2 diabetes: what is the clinical significance ? Expert Opin Pharmacother 2008;9:2295-303
78. Nissen SE, Nicholls SJ, Wolski K, et al. Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial. JAMA 2008;299:1561-73
79. Lincoff AM, Wolski K, Nicholls SJ, Nissen SE. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA 2007;298:1180-8
80. Mannucci E, Rotella CM. Future perspectives on glucagon-like peptide- 1 diabetes and cardiovascular risk. Nutr Metab Cardiovasc Dis 2008;18:639-45
81. Rendell M, Chrysant SG. Review of the safety and efficacy of linagliptin as add on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study. Postgrad Med 2011;23:183-6
82. Frederich R, Alexander JH, Fiedorek ET, et al. A systematic assessment of cardiovascular outcomes in the saxagliptin drug development program for type 2 diabetes. Postgrad Med 2010;122:16-27
83. Ban K, Noyan-Ashraf MH, Hoefer J, et al. Cardioprotective and vasodilatory action of glucagon-like peptide1 receptor-dependent and independent pathways. Circulation 2008;117:2340-50
84. Rizzo M, Rizvi AA, Spinas GA, et al. Glucose lowering and antidiabetogenic effects of incretin-based therapies: GLP-1 analogues and DPP-4 inhibitors. Expert Opin Investig Drugs 2009;18:1495-503
85. Fadini GP, Boscaro E, Albiero M, et al. The oral dipeptidyl peptidase-4 inhibitor sitagliptin increases circulating endothelial progenitor cells in patients with type 2 diabetes: possible role of stromal-derived factor-1alpha. Diabetes Care 2010;33:1607-9
86. Schweizer A, Dejager S, Foley JE, et al. Assessing the cardio-cerebrovascular safety of vildagliptin: meta-analysis of adjudicated events from a large phase III type 2 diabetes population. Diabetes Obes Metab 2010;12:485-94 .
87. Schulze MB, Shai I, Rimm EB, et al. Adiponectin and future coronary heart disease events among men with type 2 diabetes. Diabetes 2005;54:534-9
88. Ohnuma K, Uchiyama M, Yamochi T, et al. Caveolin-1 triggers T-cell activation via CD26 in association with CARMA1. J Biol Chem 2007;282:10117-31
89. Sauve M, Ban K, Momen MA, et al. Genetic deletion or pharmacological inhibition of dipeptidyl peptidase-4 improves cardiovascular outcomes after myocardial infarction in mice. Diabetes 2010;59:1063-73
90. Read PA, Khan FZ, Heck PM, et al. DPP-4 inhibition by sitagliptin improves the myocardial response to dobutamine stress and mitigates stunning in a pilot study of patients with coronary artery disease. Circ Cardiovasc Imaging 2010;3:195-201
91. Huisamen B, Genis A, Marais E, Lochner A. Pre-treatment with a DPP-4 inhibitor is infarct sparing in hearts from obese, pre-diabetic rats. Cardiovasc Drug Ther 2010;25:13-20
92. Ahren B, Landin-Olsson M, Jansson P-A, et al. Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels and reduces glucagons levels in type 2 diabetes. J Clin Endocrinol Metab 2004;89:2078-84
93. Rosenstock J, Niggli M, Maldonado-Lutomirsky M. Long-term 2 year safety and efficacy of vildagliptin compared with rosiglitazone in drug-naive patients with type 2 diabetes mellitus. Diabetes Obes Metab 2009;11:571-8
94. Bolli G, Dotta F, Rochette E, et al. Efficacy and tolerability of vildagliptin vs Pioglitazone when added to metformin: a 24-week, randomized, double-blind study. Diabetes Obes Metab 2008;10:82-90
95. Aggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroenterology 2007;132:2131-57
96. Yamagishi S, Maeda S, Matsui T. Vildagliptin inhibits oxidative stress and vascular damage in streptozotocin-induced diabetic rats. Int J Cardiol 2012;158(1):171-3
97. Dardik B, Schwartzkopf C, Stevens D, et al. The dipeptidyl peptidase IV inhibitor NVP-LAF237 improves metabolic control in diabetic and nondiabetic cynomolgus monkeys [abstract 1391-P]. Diabetes 2003;52(Suppl 1):A322
98. Ahren B, Foley JE, Pacin G, Schweizer A. Improved meal-related beta-cell function and insulin sensitivity by the dipeptidyl peptidase-IV inhibitor vildagliptin in metformin-treated patients with type 2 diabetes over 1 year. Diabetes Care 2005;28:1936-40
99. Ahren B. DPP-4 inhibitors. Best Pract Res Clin Endocrinol Metab 2007;21:517-33